A Prospective, Single-Arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Breast cancer; Prostate cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 27 Dec 2012 New source identified and integrated (German Clinical Trials Register, DRKS00003989).
- 16 Feb 2010 Actual patient number (411) added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.